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stage I, II, IIIA, and IIIB, respectively. Median age was 61.7 
years (range: 35-87). After a median planned gap of 2 weeks 
(range, 0-4; no gap in 25 patients since 2011), a boost dose 
was delivered with either IMRT (n = 16, until 2011), VMAT (n 
= 16), HT (n = 37) or 3D-CRT (n = 68). Concomitant CTX was 
delivered in 127 patients, maily using a mitomycine-
capecitabine combination (n = 117). Median follow-up was 42 
months (range: 2-97). Four-year LC, OS, DFS, and CFS rates 
were 80%, 84%, 78% and 90%, respectively. Time to 
progression was 4 months (range: 0-41). A total of 24 patients 
presented a recurrence (local only in 14, locoregional in 1, 
locoregional and distant in 1, local and distant in 3, regional 
only in 2, and distant only in 3 patients). Twelve patients 
underwent a colostomy because of local recurrence (n = 12) 
or pretreatment dysfunction (n = 2). Grade 3 acute toxicity 
was observed in 33 patients (2.4%); i.e. erythema (26/33) or 
diarrhoea (9/33). No late G3 cutaneous toxicity was 
recorded. At the time of analysis, 127 patients presented 
more than 6 months of followup and were considered 
evaluable for late toxicity: 5 of 127 patients present a late 
G3 gastrointestinal toxicity (anal incontinence). No G4 acute 
or late toxicity was recorded. No significant difference was 
observed in terms of local control or acute G3 toxicity 
between MRT techniques and 3D-CRT boost techniques. 
Conclusions: A total dose of 59.4 Gy to the anal canal and 
involved nodes, including 36 Gy to the uninvolved nodes, is 
effective and safe when delivered using modern IMRT 
techniques and daily IGRT. For these reasons, VMAT or HT 
and concurrent CTX are the standard of care in our 
institutions. 
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Purpose/Objective: To evaluate the efficacy of proton beam 
therapy (PBT) for hepatocellular carcinoma with extensive 
tumor thrombosis in the main trunk or major branches of the 
portal vein. 
Materials and Methods: Eighty patients with hepatocellular 
carcinoma were treated by PBT. There were 65 men and 15 
women, and the median age was 65 years old (range: 25 – 
88). The CTV ranged from 15.2 cm3 to 1687 cm3 (median: 
238.9 cm3). The clinical stages were 3B, 3C, 4A, and 4B in 65, 
1, 5, and 9 patients, respectively. Thirty-two patients had 
primary tumors, and 48 had recurrent tumors. The delivered 
total dose ranged from 70 to 80.47 Gy10 (median: 80.47Gy10) 
in terms of equivalent dose in 2Gy fractions. 
Results: Seventy-seven patients (96.3%) completed the 
planned treatment. Median survival rate for all the patients 
was 12 months. MST for the patients treated with PTV that 
encompassed all the detectable lesions was 26.9 months, and 
MST for the patients who had viable tumor outside of their 
PTV was 6.3 months. Local recurrence after PBT was 
observed in 3 patients. Forty-five patients died of tumor 
progression, and 28 of them had recurrence out of the PTV. 
Multivariate analysis revealed existence of viable tumor 
outside of the PTV, clinical stage, and value of des-gamma-
carboxy prothrombin as significant factors affecting the OS. 
Conclusions: PBT was effective for patients with extensive 
portal tumor thrombus, if the PTV encompassed all the 
detectable lesions.  
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Purpose/Objective: Some studies already showed that acute 
toxicity during chemo +/- radiotherapy (CT +/- RT) was 
correlated to the clinical response of the tumor. In this 
retrospective study, we report our analysis of acute toxicity 
of rectal cancer cancer patients treated with an homogenous 
schedule of CT +/- RT. 
Materials and Methods: Between 01/2010 and 08/2014, 83 
locally advanced rectal cancer patients consecutively treated 
in our institution were analyzed. All these patients received 
long-course neoadjuvant chemoradiotherapy (45 Gy on pelvic 
nodes and mesorectum and 50 Gy on gross tumor volume and 
corresponding mesorectum, delivered with a simultaneous 
integrated boost). All patients were treated with helical 
Tomotherapy (HT) and daily image guided radiotherapy, and 
all of them underwent radical surgery. Concomitant 
chemotherapy with oral capecitabine was delivered in all the 
patients. Primary endpoint of this study was to report the 
rate of acute toxicity (G2 or more) of this therapeutic 
approach and to correlate acute toxicity to the Mandard 
tumor regression rate (TRG). Toxicity were retrospectively 
scored using CTC-AE score (v. 4.0). The considered acute 
toxicity were: skin toxicity, diarrhoea, blood loss, cystitis, 
anorectal pain. We performed logistic regression analyses, 
and we correlated the TRG with the presence of acute 
toxicity (any grade), the presence of any acute toxicity grade 
> 2, and with a 'sum of toxicity' (ST) of each toxicity grades 
(i.e: this ST in a patient presenting a G2 bladder toxicity , a 
G1 pain and a G3 diarrhoea was 6, 2+1+3). 
Results: Globally, 22/83 patients presented an acute > G2 
toxicity (26.5%), with only one patients presenting a G3 acute 
skin toxicity. Data about TRG were available for 69 patients. 
Logistic regression showed that better TRG have been found 
in patients presenting higher TS, both when TRG was 
considered as an ordinal (p=0.028) or as a continuous variable 
(p=0.03). 
